ZA200103948B - Compounds useful in the treatment of inflammatory diseases. - Google Patents

Compounds useful in the treatment of inflammatory diseases. Download PDF

Info

Publication number
ZA200103948B
ZA200103948B ZA200103948A ZA200103948A ZA200103948B ZA 200103948 B ZA200103948 B ZA 200103948B ZA 200103948 A ZA200103948 A ZA 200103948A ZA 200103948 A ZA200103948 A ZA 200103948A ZA 200103948 B ZA200103948 B ZA 200103948B
Authority
ZA
South Africa
Prior art keywords
amino
phenyl
propanoic acid
oxy
compound
Prior art date
Application number
ZA200103948A
Other languages
English (en)
Inventor
Duncan Robert Armour
David Brown
Miles Stuart Congreve
Paul Martin Gore
Darren Victor Steven Green
Stuart Holman
Torquil Iain Maclean Jack
Steven Philip Keeling
Andrew Mcmurtrie Mason
Karen Morriss
Nigel Grahame Ramsden
Peter Ward
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of ZA200103948B publication Critical patent/ZA200103948B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA200103948A 1998-12-18 2001-05-15 Compounds useful in the treatment of inflammatory diseases. ZA200103948B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9828074.6A GB9828074D0 (en) 1998-12-18 1998-12-18 Therapeutically useful compounds

Publications (1)

Publication Number Publication Date
ZA200103948B true ZA200103948B (en) 2002-11-15

Family

ID=10844608

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200103948A ZA200103948B (en) 1998-12-18 2001-05-15 Compounds useful in the treatment of inflammatory diseases.

Country Status (26)

Country Link
US (1) US6867192B1 (enExample)
EP (1) EP1140837B1 (enExample)
JP (1) JP4431282B2 (enExample)
KR (1) KR20010101258A (enExample)
CN (1) CN1330637A (enExample)
AR (1) AR023727A1 (enExample)
AT (1) ATE273954T1 (enExample)
AU (1) AU760169B2 (enExample)
BR (1) BR9916282A (enExample)
CA (1) CA2355630A1 (enExample)
CO (1) CO5170533A1 (enExample)
CZ (1) CZ20012209A3 (enExample)
DE (1) DE69919580T2 (enExample)
ES (1) ES2226488T3 (enExample)
GB (1) GB9828074D0 (enExample)
GT (1) GT199900217A (enExample)
HK (1) HK1038744A1 (enExample)
HU (1) HUP0104867A3 (enExample)
IL (1) IL142908A0 (enExample)
NO (1) NO20012995L (enExample)
NZ (1) NZ511478A (enExample)
PE (1) PE20001387A1 (enExample)
PL (1) PL348059A1 (enExample)
TR (1) TR200101709T2 (enExample)
WO (1) WO2000037444A1 (enExample)
ZA (1) ZA200103948B (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001051487A1 (en) 1999-12-28 2001-07-19 Pfizer Products Inc. Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
GB0014881D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Pharmaceutical aerosol formulation
GB0014869D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Novel pharmaceutical formulation
GB0014892D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Novel pharmaceutical formulation
GB0014947D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Novel pharmaceutical formulation
GB0014851D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Novel pharmaceutical formulation
GB0014849D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Pharmaceutical aerosol formulation
GB0014883D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Novel pharmaceutical formulation
GB0127423D0 (en) * 2001-11-15 2002-01-09 Glaxo Group Ltd Process
GB0218630D0 (en) 2002-08-10 2002-09-18 Tanabe Seiyaku Co Novel compounds
WO2004103967A2 (en) 2003-05-20 2004-12-02 Genentech, Inc. Thiocarbamate inhibitors of alpha-4 integrins
KR20070029733A (ko) 2004-06-04 2007-03-14 제넨테크, 인크. 다발성 경화증의 치료 방법
US8310442B2 (en) 2005-02-23 2012-11-13 Pixtronix, Inc. Circuits for controlling display apparatus
US9261694B2 (en) 2005-02-23 2016-02-16 Pixtronix, Inc. Display apparatus and methods for manufacture thereof
US7999994B2 (en) 2005-02-23 2011-08-16 Pixtronix, Inc. Display apparatus and methods for manufacture thereof
US8159428B2 (en) 2005-02-23 2012-04-17 Pixtronix, Inc. Display methods and apparatus
US20070205969A1 (en) 2005-02-23 2007-09-06 Pixtronix, Incorporated Direct-view MEMS display devices and methods for generating images thereon
US9158106B2 (en) 2005-02-23 2015-10-13 Pixtronix, Inc. Display methods and apparatus
US8519945B2 (en) 2006-01-06 2013-08-27 Pixtronix, Inc. Circuits for controlling display apparatus
US9229222B2 (en) 2005-02-23 2016-01-05 Pixtronix, Inc. Alignment methods in fluid-filled MEMS displays
US8482496B2 (en) 2006-01-06 2013-07-09 Pixtronix, Inc. Circuits for controlling MEMS display apparatus on a transparent substrate
US7742016B2 (en) 2005-02-23 2010-06-22 Pixtronix, Incorporated Display methods and apparatus
US9082353B2 (en) 2010-01-05 2015-07-14 Pixtronix, Inc. Circuits for controlling display apparatus
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
US8526096B2 (en) 2006-02-23 2013-09-03 Pixtronix, Inc. Mechanical light modulators with stressed beams
US9176318B2 (en) * 2007-05-18 2015-11-03 Pixtronix, Inc. Methods for manufacturing fluid-filled MEMS displays
TW201438738A (zh) 2008-09-16 2014-10-16 Genentech Inc 治療進展型多發性硬化症之方法
US8169679B2 (en) 2008-10-27 2012-05-01 Pixtronix, Inc. MEMS anchors
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
KR101659642B1 (ko) 2010-02-02 2016-09-26 픽스트로닉스 인코포레이티드 디스플레이 장치를 제어하기 위한 회로
WO2011097252A2 (en) 2010-02-02 2011-08-11 Pixtronix, Inc. Methods for manufacturing cold seal fluid-filled display apparatus
WO2013101771A2 (en) 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
AR091305A1 (es) 2012-01-31 2015-01-28 Genentech Inc ANTICUERPOS ANTI-IgE Y SUS METODOS DE USO
US9134552B2 (en) 2013-03-13 2015-09-15 Pixtronix, Inc. Display apparatus with narrow gap electrostatic actuators
WO2015181837A2 (en) * 2014-05-30 2015-12-03 Sphaera Pharma Pvt. Ltd. Novel compounds as anti-tubercular agents
PL3319639T3 (pl) * 2015-07-08 2021-03-08 Axerovision, Inc. Kompozycje farmaceutyczne zawierające antagonistę integryny alfa4 do stosowania w leczeniu stanów zapalnych oka
HRP20250052T1 (hr) 2015-10-06 2025-03-14 F. Hoffmann - La Roche Ag Postupak liječenja multiple skleroze
HRP20220479T1 (hr) * 2016-06-01 2022-05-27 Athira Pharma, Inc. Spojevi
CN109722455B (zh) * 2017-10-31 2022-03-11 中国科学院天津工业生物技术研究所 微生物发酵生产谷内酯的方法、工程菌及应用
WO2019246455A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
ES3003232T3 (en) 2018-10-30 2025-03-10 Gilead Sciences Inc Compounds for inhibition of alpha4beta7 integrin
ES2987796T3 (es) 2018-10-30 2024-11-18 Gilead Sciences Inc Derivados de N-benzoil-fenilalanina como inhibidores de la integrina alfa4beta7 para el tratamiento de enfermedades inflamatorias
CN112969687B (zh) 2018-10-30 2024-08-23 吉利德科学公司 作为α4β7整合素抑制剂的喹啉衍生物
CA3114240C (en) 2018-10-30 2023-09-05 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
CN114222730B (zh) 2019-08-14 2024-09-10 吉利德科学公司 用于抑制α4β7整合素的化合物
JP2023546915A (ja) * 2020-10-21 2023-11-08 アズーラ オフサルミックス エルティーディー． 眼障害を処置するための化合物および方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1593858A1 (de) 1967-03-02 1970-10-29 Hoechst Ag Verfahren zur Herstellung tyrosinhaltiger Peptide und deren Derivaten
US4105602A (en) 1975-02-10 1978-08-08 Armour Pharmaceutical Company Synthesis of peptides with parathyroid hormone activity
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
AU728435B2 (en) 1997-05-29 2001-01-11 Merck & Co., Inc. Sulfonamides as cell adhesion inhibitors
ES2257808T3 (es) 1997-05-29 2006-08-01 MERCK & CO., INC. (A NEW JERSEY CORP.) Acidos biarilalcanoicos como inhibidores de adhesion celular.
CA2291778A1 (en) 1997-05-29 1998-12-03 Merck & Co., Inc. Heterocyclic amide compounds as cell adhesion inhibitors
ATE256699T1 (de) * 1997-05-30 2004-01-15 Celltech Therapeutics Ltd Entzündungshemmende tyrosin-derivate

Also Published As

Publication number Publication date
HUP0104867A3 (en) 2002-06-28
ATE273954T1 (de) 2004-09-15
US6867192B1 (en) 2005-03-15
ES2226488T3 (es) 2005-03-16
PL348059A1 (en) 2002-05-06
CZ20012209A3 (cs) 2001-09-12
GT199900217A (es) 2001-06-09
HUP0104867A2 (hu) 2002-04-29
GB9828074D0 (en) 1999-02-17
NO20012995D0 (no) 2001-06-15
PE20001387A1 (es) 2000-12-22
EP1140837B1 (en) 2004-08-18
BR9916282A (pt) 2001-10-02
JP4431282B2 (ja) 2010-03-10
CA2355630A1 (en) 2000-06-29
AR023727A1 (es) 2002-09-04
IL142908A0 (en) 2002-04-21
AU3039100A (en) 2000-07-12
EP1140837A1 (en) 2001-10-10
WO2000037444A1 (en) 2000-06-29
CO5170533A1 (es) 2002-06-27
NO20012995L (no) 2001-08-15
TR200101709T2 (tr) 2001-12-21
JP2002533326A (ja) 2002-10-08
HK1038744A1 (zh) 2002-03-28
AU760169B2 (en) 2003-05-08
CN1330637A (zh) 2002-01-09
NZ511478A (en) 2003-08-29
DE69919580T2 (de) 2005-09-01
DE69919580D1 (de) 2004-09-23
KR20010101258A (ko) 2001-11-14

Similar Documents

Publication Publication Date Title
ZA200103948B (en) Compounds useful in the treatment of inflammatory diseases.
EP0991619B1 (en) Inhibitors of alpha 4-beta 1 mediated cell adhesion
AU718926B2 (en) Cell adhesion inhibitors
US6630503B1 (en) Cell adhesion inhibitors
US20020028933A1 (en) Thioamide derivatives
EP1144365B1 (en) Inhibitors of alpha-4 beta-1 mediated cell adhesion
SK145298A3 (en) Antivirally active heterocyclic azahexane derivatives, process for their preparation, pharmaceutical composition containing same and their use
WO2001068586A2 (en) α4β1 AND α4β7 INTEGRIN INHIBITORS
JP2003503350A (ja) Ｖｌａ−４インヒビター化合物
MXPA02005564A (es) 4-pirimidinil-n-acil-l.fenilalaninas.
US7265146B2 (en) Integrin receptor inhibitors
KR20010034317A (ko) Ｖｌａ-4 길항제
CA2064955A1 (en) Amino acid derivatives
US6407065B1 (en) VLA-4 antagonists
MXPA01006140A (en) Compounds useful in the treatment of inflammatory diseases
JPH09188631A (ja) Ｆａｓリガンド可溶化抑制薬
US20020091142A1 (en) Alpha4beta1 and alpha4beta7 integrin inhibitors
HK1035726A1 (en) A vla-4 inhibitor: omepupa-v
HK1035726B (en) A vla-4 inhibitor: omepupa-v